Rheonova was present at the Congrès de Pneumologie de Langue Française 2022 in Lille where we presented our latest work on bronchial mucus heterogeinity: micro- and macro-rheology study Abstract In lung muco-obstructive diseases, such as cystic fibrosis, chronic...
News
Rheonova participated at ECFS basic Science 2022
Rheonova was present at the ECFS basic science 2022 at Albufeira. Our PhD student Lydia ESTEBAN ENJUTO presented her work on cystic fibrosis sputum handling for rheology. Muco-obstructive diseases, including cystic fibrosis, COPD or severe asthma feature an alteration...
Happy New Year 2022!
Rheonova wishes you happy new year 2022!this past year have been rich, challenging and exciting, here is a small preview!
Rheomuco CE marking funding
Rheonova is supported by the Auvergne Rhône-Alpes region to ensure compliance with the new European regulation for CE marking of our medical device Rheomuco and the associated quality management system. The region, in collaboration with the Agency, Lyonbiopole and...
Rheonova granted the first regional PSPC
We are happy to announce that Rheonova, in collaboration with Cedrat Technologies and the laboratories TIMA and LRP, have been granted the regional PSPC for the project MucoPiezoRheo. This project aims to develop a medical device for personalized diagnosis and...
RheoCare project has received funding from the EU’s H2020 programme
Rheonova is proud to announce that the RheoCare project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 889360. The aim is to implement an automated sample manipulation device on the Rheomuco....
Meet us at the NACFS in Nashville from October 31 to November 2, 2019
North American Cystic Fibrosis Conference will stand in few days. Rheonova team would be glad to meet you there and present its Poster n°529 “RHEOLOGICAL SIGNATURE OF INDUCTION ON CF SPUTUM: SPONTANEOUS VERSUS HYPERTONIC SALINE VERSUS RHDNASE”
Pioneer in the chronic respiratory diseases sector, Rheonova opens its capital
Following Rheomuco's first sales to research laboratories in Europe, Rheonova wishes to boost its commercial activity. And to bring Rheomuco to the patient's bedside, 2 new clinical trials are underway. The first at Cochin Hospital for patients with cystic fibrosis...
13 European companies selected under EIT Health Go Global program to reach canadian market and healthtech innovation hubs
Following an intensive selection process through a dedicated European-Canadian jury, thirteen European companies are laureates of the 2019 edition of the GoGlobal Canada program and will benefit from a unique gateway to Canada. Click here for the full press release